Lyra Therapeutics (LYRA) SC 13G Lyra Therapeutics / Vestal Point Capital ownership change

EXHIBIT 99.1

JOINT ACQUISITION STATEMENT
PURSUANT TO RULE 13d-1(k)

The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

DATED: February 13, 2024

VESTAL POINT CAPITAL, LP
By: VESTAL POINT CAPITAL, LLC, its general partner
By:	/s/ Ryan Wilder
Name:	Ryan Wilder
Title:	Chief Investment Officer and Managing Partner
/s/ Ryan Wilder
Ryan Wilder